Drug intelligence / Profile preview

COMPOUND 5E

Development stage: Preclinical
Modality: Small Molecules

Overview

COMPOUND 5E is a novel synthetic pyrazole pyrazoline thiazole derivative being investigated for its potential as a breast cancer therapeutic. Preclinical studies have demonstrated its antitumor activity, along with anti-inflammatory and antioxidant properties. It has shown efficacy in reducing the levels of key cytokines such as Tumor Necrosis Factor alpha (TNF-α), Interleukin-6 (IL-6), and Transforming Growth Factor-beta (TGF-β), and also decreases malondialdehyde (MDA) levels, indicating a reduction in oxidative stress. The compound has exhibited both in vitro and in vivo anticancer activity in preclinical models.

Other names: 5-(2-fluorophenoxy)-4-(3-(4-fluorophenyl)-1-(4-(4-fluorophenyl)thiazol-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)-3-methyl-1-phenyl-1H-pyrazole

Targets

MAPK12 (Mitogen-activated protein kinase 12)

Beyond the preview

Go deeper on COMPOUND 5E.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COMPOUND 5E.

Explore the full profile